ArticleInternational journal of clinical oncology2021
The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
Masayuki Sekine et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.